Today in Philippine History (Philatelic Edition Series 2):
September 20, 2021
Pfizer Inc. and BioNTech SE announced the results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, which is a smaller dose than the 30 µg dose used for people 12 and older.
The antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 µg doses.
The 10 µg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. These are the first results from a pivotal trial of a COVID-19 vaccine in this age group.
The Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the virus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019, and the disease quickly spread worldwide, resulting in the COVID-19 pandemic.
(Design, concept, stamps and research: Richard Allan B. Uy) All rights reserved
Photo credit: wikipedia.org
Posts
No comments:
Post a Comment